(Q84189818)
Statements
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers (English)
Himanshu Naik
Majid Vakilynejad
Jingtao Wu
Prabhakar Viswanathan
Nobuhito Dote
Tomoaki Higuchi
Eckhard Leifke